Drug intelligence / Profile preview

Chaiqin Qingning

Development stage: Phase 4
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

Chaiqin Qingning is a Traditional Chinese Medicine (TCM) capsule formulation used to treat acute upper respiratory tract infections, common colds, and fevers, particularly those presenting with wind-warm syndrome. The preparation is primarily composed of extracts from Radix Bupleuri (Chaihu) and Radix Scutellariae (Huangqin). It functions by clearing heat and resolving the exterior, providing antipyretic and anti-inflammatory effects. Clinical studies, including those conducted at Longhua Hospital, have evaluated its efficacy in reducing body temperature and alleviating symptoms associated with viral respiratory infections.

Brand names: Chaiqin Qingning
Other names: Chaiqin Qingning CapsuleChai Qin Qing Ning

Targets

IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Chaiqin Qingning.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chaiqin Qingning.